Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: A systematic review

Journal of Clinical Oncology

Volumn 22, Issue 21, 2004, Pages 4418-4424

  Roffe, Liz ^a   Schmidt, Katja ^a   Ernst, Edzard ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; UBIDECARENONE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; DRUG DERIVATIVE; UBIQUINONE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG TOLERABILITY; HEART PROTECTION; HUMAN; LIVER PROTECTION; LIVER TOXICITY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; CELL PROTECTION; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; NEOPLASM;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CONTROLLED CLINICAL TRIALS; CYTOPROTECTION; HUMANS; NEOPLASMS; UBIQUINONE;

EID: 16544375906     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.02.034     Document Type: Review

References (44)

1. Astin JA: Why patients use alternative medicine: Results of a national study. JAMA 279:1548-1553, 1998
2. Zappa SB, Cassileth BR: Complementary approaches to palliative oncological care. J Nurs Care Qual 18:22-26, 2003
3. Eisenberg DM, Davis RB, Ettner SL, et al: Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 280:1569-1575, 1998
4. Ernst E, Cassileth BR: The prevalence of complementary/alternative medicine in cancer: A systematic review. Cancer 83:777-782, 1998
5. Ashikaga T, Bosompra K, O'Brien P, et al: Use of complementary and alternative medicine by breast cancer patients: Prevalence, patterns and communication with physicians. Support Care Cancer 10:542-548, 2002
6. Schmidt K, Ernst E: Assessing websites on complementary and alternative medicine for cancer. Ann Oncol 15:733-742, 2004
7. Damkier A, Jensen AB, Rose C: Kraeftpatienters brug af Q10. Ugeskr Laeger 156:813-818, 1994
8. Tran MT, Mitchell TM, Kennedy DT, et al: Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy 21: 797-806, 2001
9. Cassileth BR, Lucarelli CD (eds): Coenzyme Q10, in Herb-Drug Interactions in Oncology. Ontario, Canada, B.C. Decker Inc, 2003, pp 109-113
10. Jellin JM, Batz F, Hitchens K: Coenzyme Q10, in Pharmacist's Letter/Prescriber's Letter: Natural Medicines Comprehensive Database. Stockton, CA, Therapeutic Research Center, 1999, 271-273
11. Folkers K, Shizukuishi S, Takemura K, et al: Increase in levels of IgG in serum of patients treated with coenzyme Q10. Res Commun Chem Pathol Pharmacol 38:335-338, 1982
12. Folkers K, Morita M, McRee J Jr: The activities of coenzyme Q10 and vitamin B6 for immune responses. Biochem Biophys Res Commun 193:88-92, 1993
13. Lockwood K, Moesgaard S, Yamamato T, et al: Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 212:172-177, 1995
14. Lockwood K, Moesgaard S, Folkers K: Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme 010. Biochem Biophys Res Commun 199:1504-1508, 1994
15. Lockwood K, Moesgaard S, Hanioka T, et al: Apparent partial remission of breast cancer in high risk patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 15:S231-S40, 1994 (suppl)
16. Weber C, Bysted A, Holmer G: Coenzyme Q10 in the diet-daily intake and relative bioavailablity. Mol Aspects Med 18:5251-5254, 1997 (suppl)
17. Crane FL: Biochemical functions of coenzyme Q(10). J Am Coll Nutr 20:591-598, 2001
18. Folkers K, Osterborg A, Nylander M, et al: Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 234:296-299, 1997
19. Jolliet P, Simon N, Barre J, et al: Plasma coenzyme Q10 concentrations in breast cancer: Prognosis and therapeutic consequences. Int J Clin Pharmacol Ther 36:506-509, 1998
20. Kishi T, Watanabe T, Folkers K: Bioenergetics in clinical medicine: Prevention by forms of coenzyme Q of the inhibition by Adriamycin of coenzyme Q10 enzymes in mitochondria of the myocardium. Proc Natl Acad Sci U S A 73:4653-4656, 1976
21. Solaini G, Ronca G, Bertelli A: Inhibitory effects of several anthracyclines on mitochondrial respiration and coenzyme Q10 protection. Drugs Exp Clin Res 11:533-537, 1985
22. Hussain SP, Hofseth U, Harris CC: Radical causes of cancer. Nat Rev Cancer 3:276-285, 2003
23. Pai VB, Nahata MC: Cardiotoxicity of chemotherapeutic agents: Incidence, treatment and prevention. Drug Saf 22:263-302, 2000
24. Reynolds James EF (ed): Martindale The Extra Pharmacopoeia (ed 31). London, United Kingdom, Royal Pharmaceutical Society, 1996, pp 567, 1764
25. Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17:1-12, 1996
26. Lesperance ML, Olivotto IA, Forde N, et al: Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: An historical cohort study. Breast Cancer Res Treat 76: 137-143, 2002
27. Imanaka K, Izumiyama K, Sakaguchi T, et al: Effect of coenzyme Q10 and Azelastin on protecting radiation pneumonitis with lung cancer. J Jpn Soc Cancer Ther 29:2010-2015, 1994
28. Akihama T, Nakamoto Y, Shindo T, et al: Clinical evaluation by double blind method of the protective effects of coenzyme Q10 on adverse reactions of anthracycline antibiotics, especially hair loss. Can To Kagaku Ryoho 10:2125-2129, 1983
29. Okuma K, Furuta I, Ota K: Protective effect of coenzyme Q10 in cardiotoxicity induced by Adriamycin. Can To Kagaku Ryoho 11:502-508, 1984
30. Takimoto M, Sakurai T, Kodama K, et al: Protective effect of CoQ10 administration for the myocardial intoxication during the FAC therapy. Gan To Kagaku Ryoho 9:116-121, 1982
31. Iarussi D, Auricchio U, Agretto A, et al: Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: Control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med 15:S207-S212, 1994 (suppl)
32. Lucarelli G, Angelucci C, Giardini G, et al: Ubidecarenone and toxic cardiopathy from antiblastic therapy with daunoblastine. Boll Chim Farm 125:534-539, 1986
33. Thibault A, Samid D, Tompkins AC, et al: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2:483-491, 1996
34. Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K: Anthracycline-induced cardiotoxiciy: Clinical course, risk factors, pathogenesis, detection and prevention-Review of the literature. Med Sci Monit 6:411-420, 2000
35. Ganz WI, Sridahar KS, Gana SS, et al: Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 53:461-470, 1996
36. Kaikkonen J, Tuomainen TP, Nyyssonen K, et al: Coenzyme Q10: Absorption, antioxidative properties, determinants, and plasma levels. Free Radic Res 36:389-397, 2002
37. Reis F, Hermida RC, Souza I, et al: Circadian and seasonal variation of endogenous ubiquinone plasma level. Chronobiol Int 19:599-614, 2002
38. Eaton S, Skinner R, Hale JP, et al: Plasma coenzyme Q10 in children and adolescents undergoing doxorubicin therapy. Clin Chim Acta 302:1-9, 2000
39. Spigset O: Reduced effect of warfarin caused by ubidecarenone. Lancet 344:1372-1373, 1994
40. Landbo C, Almdal TP: Interaction between warfarin and coenzyme Q10. Ugeskr Laeger 160:3226-3227, 1998
41. ConsumerLab: Product review: Coenzyme Q10. http://www.consumerlab.com/ results/coq10.asp
42. Lamson DW, Brignall MS: Antioxidants in cancer therapy: Their actions and interactions with oncologic therapies. Altern Med Rev 4:304-329, 1999
43. Shinozawa S, Gomita Y, Araki Y: Tissue concentration of doxorubicin (Adriamycin) in mouse pretreated with alpha-tocopherol or coenzyme Q10. Acta Med Okayama 45:195-199, 1991
44. Zhou Q, Chowbay B: Effect of coenzyme Q10 on the disposition of doxorubicin in rats. Eur J Drug Metab Pharmacokinet 27:185-192, 2002